Smith Robert G
*STOP-Studying Opioid Harm 501.3c, 723 Lucerne Cir, Ormond Beach, FL 32174.
J Am Podiatr Med Assoc. 2023 May-Jun;113(3). doi: 10.7547/22-150.
Podiatric physicians have come to realize that opioid use disorder (OUD) is a public health crisis causing morbidity, mortality, lost productivity, and legal cost in the United States. Opioid analgesics are efficient first-line pain relievers for acute and chronic lower-extremity pain syndrome. Perioperative pain management strategies have been proposed using opioid stewardship, but there are few standardized protocols to guide podiatric medical providers treating patients with OUD. First, we describe the pharmacology of therapeutic agents used as medications for addiction treatment for OUD and substance use disorder (SUD). Second, we offer criteria for selecting acute pain and perioperative management in patients with OUD and SUD per current medical literature. Finally, we review the literature applying opioid stewardship in the context of prescribing opioid analgesics in the presence of OUD and SUD. Three hypothetical clinical scenarios grounded in clinical-based literature are described with congruent data and founded guidelines. The first and second scenarios describe acute pain and perioperative management in patients with OUD receiving methadone and buprenorphine-naloxone, respectively. The third scenario describes acute pain and perioperative management in a patient with SUD receiving intravenous naltrexone. We hope that the lower-extremity specialist will appreciate that thoughtful management of acute perioperative pain among patients who receive medications for addiction treatment for OUD is critically important given the risks of destabilization during the perioperative period. The literature reveals the lack of rigorous evidence on acute pain management in patients who receive medication for OUD; however, some clinical evidence supports the practice of continuing methadone or buprenorphine for most patients during acute pain episodes.
足病医生已经意识到,在美国,阿片类药物使用障碍(OUD)是一场公共卫生危机,会导致发病率、死亡率上升,生产力下降以及产生法律成本。阿片类镇痛药是治疗急慢性下肢疼痛综合征的有效一线止痛药。虽然已经提出了使用阿片类药物管理的围手术期疼痛管理策略,但很少有标准化方案来指导足病医疗服务提供者治疗患有阿片类药物使用障碍的患者。首先,我们描述用于治疗阿片类药物使用障碍和物质使用障碍(SUD)的治疗药物的药理学。其次,根据当前医学文献,我们提供在患有阿片类药物使用障碍和物质使用障碍的患者中选择急性疼痛和围手术期管理的标准。最后,我们回顾在存在阿片类药物使用障碍和物质使用障碍的情况下,在开具阿片类镇痛药时应用阿片类药物管理的文献。基于临床文献描述了三种假设的临床场景,并给出了相应的数据和有依据的指导方针。第一个和第二个场景分别描述了接受美沙酮和丁丙诺啡 - 纳洛酮的阿片类药物使用障碍患者的急性疼痛和围手术期管理。第三个场景描述了接受静脉注射纳曲酮的物质使用障碍患者的急性疼痛和围手术期管理。我们希望下肢专科医生能够认识到,鉴于围手术期不稳定的风险,对于接受阿片类药物使用障碍治疗药物的患者,精心管理急性围手术期疼痛至关重要。文献显示,对于接受阿片类药物使用障碍治疗药物的患者,缺乏关于急性疼痛管理的严格证据;然而,一些临床证据支持在急性疼痛发作期间,对大多数患者继续使用美沙酮或丁丙诺啡的做法。